^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2020
    Title:

    LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)

    Published date:
    09/19/2020
    Excerpt:
    ...Pts with ex19del had better HR than L858R (HR = 0.67, 0.45-0.99; 0.72, 0.48-1.09)...Prolonged PFS by INV (HR = 0.71, 95% CI 0.53-0.95) was observed...ORR was 77.1% and 73.7% in AG and G arms (p = 0.5572)…
    Trial ID:
    NCT02824458
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

    Excerpt:
    ...Documented evidence of tumor harboring an activating EGFR mutation (Example 19 del and L858R)...
    Trial ID:
    NCT02824458